2.1 Study Design
This study used a single-center cross-sectional design. We enrolled 49
pediatric patients with HM (Group 1) and 50 healthy volunteers (Group
2), who presented to Atatürk University Faculty of Dentistry Department
of Pedodontics between 2018 and 2020 for oncological treatment. Children
with acute myelocytic leukemia (AML), ALL, were included in the HM
group. Children with malign melanoma, hodgkin lymphoma or non-hodgkin
lymphoma, were excluded in the HM group because the number of children
with these cancers was low. Healthy children presenting to the clinic
for various reasons were included in the control group. The children in
the control group did not have any systemic disease.